Entrada Therapeutics Stock (NASDAQ:TRDA)
Previous Close
$17.28
52W Range
$11.35 - $21.79
50D Avg
$18.44
200D Avg
$15.74
Market Cap
$658.22M
Avg Vol (3M)
$130.14K
Beta
-0.27
Div Yield
-
TRDA Company Profile
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
TRDA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| CNTA | Centessa Pharmaceuticals plc |
| RLYB | Rallybio Corporation |
| TYRA | Tyra Biosciences, Inc. |
| VIGL | Vigil Neuroscience, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| IRON | Disc Medicine, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| PEPG | PepGen Inc. |
| THRD | Third Harmonic Bio, Inc. |
| PHVS | Pharvaris N.V. |
| GNTA | Genenta Science S.p.A. |
| MOLN | Molecular Partners AG |
| OPT | Opthea Limited |